89977-46-8

Upstream product

• 69722-29-8 5-amino-1-(2-pyridinyl)-1H-pyrazole-4-carboxylic acid,ethyl ester 
• 4930-98-7 pyrid-2-ylhydrazine 
• 58243-08-6 (E)-3-ethoxyacrylonitrile 
• 126583-37-7 5-amino-1-(2-pyridyl)-1H-pyrazole-4-carboxylic acid 

Downstream Products

• 364728-10-9 4,5-difluoro-2-[[1-(2-pyridinyl)-1H-pyrazol-5-yl]amino]benzoic acid 
• 364728-00-7 5-chloro-2-[[1-(2-pyridinyl)-1H-pyrazol-5-yl]amino]benzoic acid 
• 1620335-76-3 4-chloro-N-(1-(pyridin-2-yl)-1H-pyrazol-5-yl)benzenesulfonamide 
• 1620335-77-4 N-(1-(pyridin-2-yl)-1H-pyrazol-5-yl)-4-(trifluoromethyl)benzenesulfonamide 

Relevant academic research and scientific papers

Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists

The neuropeptide oxytocin has been implicated in multiple central nervous system functions in mammalian species. Increased levels have been reported to improve trust, alleviate symptoms related to autism and social phobias, and reduce social anxiety. Hoffman-La Roche published a patent claiming to have found potent small molecule oxytocin receptor agonists, smaller than the first non-peptide oxytocin agonist reported, WAY 267,464. We selected two of the more potent compounds from the patent and, in addition, created WAY 267,464 hybrid structures and determined their oxytocin and vasopressin receptor activity. Human embryonic kidney and Chinese hamster ovary cells were used for the expression of oxytocin or vasopressin 1a receptors and activity assessed via IP1 accumulation assays and calcium FLIPR assays. The results concluded that the reported compounds in the patent and the hybrid structures have no activity at the oxytocin or vasopressin 1a receptors.

Compounds derived from diaminopyrazole substituted by a heteroaromatic radical and their use in oxidation dyeing of keratimous fibers

The invention concerns compounds derived from diaminopyrazole of formula (I), wherein: Ar is a 5- or 6-membered heteroaromatic radical capable of being condensed with one or several heteroaromatic cycles each comprising 5 or 6 members, and their physiologically acceptable addition salts with and acid. The invention also concerns compositions containing such a compound for oxidation dyeing of keratinous fibres and the method using said compositions.

HSP INDUCTOR

An agent for inducing HSP, comprising a compound represented by the formula (I): ???wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, etc.; R2 is absent, a hydrogen atom or a hydrocarbon group which maybe substituted; R3 is a heterocyclic group which may be substituted; X, Y and Z are, respectively, a hydrogen, a halogen, a nitrile, a hydrocarbon group which may be substituted, or X and Y may bind to each other to form ring A, or Y and Z may bind to each other to form ring B; bond portions indicated by a solid line and a broken line are, respectively, a single bond or a double bond, and bond portions indicated by a broken line are, respectively, a single bond or absent; ring A is a homocyclic or heterocyclic 5- to 7-membered ring which may be substituted; ring B is a homocyclic or heterocyclic 5- to 7-membered ring which may be substituted; and n is an integer of 0 or 1, or a salt thereof;

Condensed pyrazole derivatives, process for producing the same and use thereof

Novel pharmaceutical compositions for inhibiting Th2-selective immune response and pharmaceutical compositions for inhibiting cyclooxygenase comprising condensed pyrazole derivatives represented by the general formula (I): or salts thereof.